Market Outline: Cervical Ripening Drugs Market
Cervical ripening is defined as the softening of cervix prior to onset of labor contractions and it is necessary for the cervical dilation and passage of fetus. Cervix softens, thins, dilates, and relaxes in response to the uterine contractions and allows the cervix to easily pass over the fetal part during labor. Cervical ripening drugs are used before the induction of labor for the dilatation of cervix. The ripening of cervix is associated with the reduced collagen fiber strength, decrease in collagen fiber alignment, and diminished the tensile strength of extracellular cervical matrix. The common techniques used for the cervical ripening are mechanical interventions such as insertion of cervical catheters and dilators and application of cervical ripening agents such as prostaglandins.
Market Dynamics: Cervical Ripening Drugs Market
Growing usage of cervical ripening drugs before the induction of labor, rise in R&D; activities for the innovation of newer drugs, increase in awareness about cervical ripening drugs in developed and developing countries, low cost of drugs, and government initiations for improving the baby deliveries are anticipated to fuel the cervical ripening drugs market over the forecast period. However, stringent regulatory policies for product approval, adverse effects associated with the cervical ripening drugs, and alternative procedures for the childbirth are expected to hinder the growth of surgical ripening drugs market over the forecast timeframe.
Market Scope: Cervical Ripening Drugs Market
Cervical ripening drugs market is segmented on the basis of drug type, route of administration, distribution channel, and region
Based on the drug type, market is segmented into the following:
Prostaglandins
Oxytocin
Progesterone Receptor Antagonists
Relaxin
Estrogen
Others
Based on the route of administration, market is segmented into the following:
Oral
Intravenous
Vaginal
Based on the distribution channel, market is segmented into the following:
Hospital Pharmacies
Retail Pharmacies
Others
Market Summary: Cervical Ripening Drugs Market
Cervical ripening drugs market is projected to grow at a significant rate with increase in the usage of cervical ripening drugs prior to the induction of labor. Moreover, acquisitions and mergers, product approvals, and product launchings are the key strategies adopted by market players to generate increased revenue in cervical ripening drugs market. For instance, in February 2012, Ferring Pharmaceuticals acquired Cytokine PharmaSciences Inc. and the acquisition includes manufacturing assets of Cervidil (Dinoprostone) in U.S. and Canada.
Regional Analysis: Cervical Ripening Drugs Market
Geographically, global cervical ripening drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America cervical ripening drugs market growth driven by increase in the R&D; for the innovation of newer drugs and high awareness about the cervical ripening drugs among the physicians. Europe cervical ripening drugs market has a lucrative growth owing to high adoption of cervical ripening drugs, launching of newer drugs by the market players. Asia Pacific cervical ripening drugs market has significant share owing to rise in number of female population, government initiations for the baby birth, and increase in the using of cervical ripening drugs before the induction of labor are propel the market. Middle East and Africa cervical ripening drugs market has a prominent share owing to increase in the number of births and rise in awareness about the cervical ripening drugs are in the region.
Competition Assessment: Cervical Ripening Drugs Market
Some of the players in the global cervical ripening drugs market include:
Ferring B.V. (Switzerland)
Azanta A/S (Denmark)
Novartis AG (Switzerland)
GlaxoSmithKline plc (U.K.)
AstraZeneca plc (U.K.)
Pfizer, Inc. (U.S.)
Bayer AG (Germany)
Notable Market Developments: Cervical Ripening Drugs Market
In February 2016, Azanta A/S filed marketing authorization application in Nordic countries for Angusta (Misoprostol), which is indicated in induction of labor
1. Executive summary
2. Global Cervical Ripening Drugs Market Introduction
2.1. Global Cervical Ripening Drugs Market – Taxonomy
2.2. Global Cervical Ripening Drugs Market –Definitions
2.2.1. Drug class
2.2.2. Distribution Channel
3. Global Cervical Ripening Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Cervical Ripening Drugs Market Dynamics – Factors Impact Analysis
3.6. Global Cervical Ripening Drugs Market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Cervical Ripening Drugs Market – Product Innovations
4. Global Cervical Ripening Drugs Market Analysis, 2014 - 2018 and Forecast, 2019 – 2025
4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. Global Cervical Ripening Drugs Market, By Drug Class, 2014 - 2018 and Forecast, 2019 - 2025
5.1. Drug Class Analysis (2014-2018) and Forecast (2019-2025) by Revenue (USD Mn) and Y-o-Y Growth (%)
5.1.1. Prostaglandins
5.1.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.1.3. Market Opportunity Analysis
5.1.2. Oxytocin
5.1.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.2.3. Market Opportunity Analysis
5.1.3. Progesterone Receptor Antagonists
5.1.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.3.3. Market Opportunity Analysis
5.1.4. Relaxin
5.1.4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.4.3. Market Opportunity Analysis
5.1.5. Estrogen
5.1.5.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
5.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.5.3. Market Opportunity Analysis
5.1.6. Others
5.1.6.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
5.1.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.6.3. Market Opportunity Analysis
6. Global Cervical Ripening Drugs Market Forecast, By Route of Administration, 2014 - 2018 and Forecast, 2019 - 2025
6.1.1. Oral
6.1.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
6.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.1.3. Market Opportunity Analysis
6.1.2. Intravenous
6.1.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
6.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.2.3. Market Opportunity Analysis
6.2. Vaginal
6.2.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
6.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.1.3. Market Opportunity Analysis
7. Market Opportunity Analysis Global Cervical Ripening Drugs Market Forecast, By Distribution Channel, 2014 - 2018 and Forecast, 2019 - 2025
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
8. Global Cervical Ripening Drugs Market Forecast, By Region, 2014 - 2018 and Forecast, 2019 - 2025
8.1. North America
8.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.5.3. Market Opportunity Analysis
8.6. Global Cervical Ripening Drugs Market - Opportunity Analysis Index, By Drug Class, Diseases Type, Distribution Channel, and Region, 2019 – 2025
9. North America Cervical Ripening Drugs Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
9.1.1. Drug Class Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1.1. Prostaglandins
9.1.1.2. Oxytocin
9.1.1.3. Progesterone Receptor Antagonists
9.1.1.4. Relaxin
9.1.1.5. Estrogen
9.1.1.6. Others
9.1.2. Route of Administration Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.2.1. Oral
9.1.2.2. Intravenous
9.1.2.3. Vaginal
9.1.3. Distribution Channel Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.3.1. Hospital Pharmacies
9.1.3.2. Retail Pharmacies
9.1.3.3. Others
9.1.4. Country Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.1.4.1. U.S.
9.1.4.2. Canada
9.1.5. North America Cervical Ripening Drugs Market - Opportunity Analysis Index, By Drug Class, Route of Administration, Distribution Channel and Country, 2019 – 2025
9.1.6. North America Cervical Ripening Drugs Market Dynamics – Trends
10. Europe Cervical Ripening Drugs Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
10.1.1. Drug Class Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.2. Drug Class Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.2.1. Prostaglandins
10.1.2.2. Oxytocin
10.1.2.3. Progesterone Receptor Antagonists
10.1.2.4. Relaxin
10.1.2.5. Estrogen
10.1.2.6. Others
10.1.3. Route of Administration Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Oral
10.1.3.2. Intravenous
10.1.3.3. Vaginal
10.1.4. Distribution Channel Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Hospital Pharmacies
10.1.4.2. Retail Pharmacies
10.1.4.3. Others
10.1.5. Country Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.5.1. Germany
10.1.5.2. UK
10.1.5.3. France
10.1.5.4. Spain
10.1.5.5. Italy
10.1.5.6. Russia
10.1.5.7. Poland
10.1.5.8. Rest of Europe
10.1.6. Europe Cervical Ripening Drugs Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2019 – 2025
10.1.7. Europe Cervical Ripening Drugs Market Dynamics – Trends
11. Asia-Pacific Cervical Ripening Drugs Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
11.1.1. Drug Class Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.2. Drug Class Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.2.1. Prostaglandins
11.1.2.2. Oxytocin
11.1.2.3. Progesterone Receptor Antagonists
11.1.2.4. Relaxin
11.1.2.5. Estrogen
11.1.2.6. Others
11.1.3. Route of Administration Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Oral
11.1.3.2. Intravenous
11.1.3.3. Vaginal
11.1.4. Distribution Channel Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.4.1. Hospital Pharmacies
11.1.4.2. Retail Pharmacies
11.1.4.3. Others
11.1.5. Country Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.1.5.1. Japan
11.1.5.2. China
11.1.5.3. India
11.1.5.4. ASEAN
11.1.5.5. Australia & New Zealand
11.1.5.6. Rest of Asia-Pacific
11.1.6. Asia-Pacific Cervical Ripening Drugs Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2019 – 2025
11.1.7. Europe Cervical Ripening Drugs Market Dynamics – Trends
12. Latin America Cervical Ripening Drugs Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
12.1.1. Drug Class Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.2. Drug Class Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.2.1. Prostaglandins
12.1.2.2. Oxytocin
12.1.2.3. Progesterone Receptor Antagonists
12.1.2.4. Relaxin
12.1.2.5. Estrogen
12.1.2.6. Others
12.1.3. Route of Administration Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Oral
12.1.3.2. Intravenous
12.1.3.3. Vaginal
12.1.4. Distribution Channel Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Hospital Pharmacies
12.1.4.2. Retail Pharmacies
12.1.4.3. Others
12.1.5. Country Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.5.1. Brazil
12.1.5.2. Mexico
12.1.5.3. Argentina
12.1.5.4. Venezuela
12.1.5.5. Rest of Latin America
12.1.6. Latin America Cervical Ripening Drugs Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2019 – 2025
12.1.7. Latin America Cervical Ripening Drugs Market Dynamics – Trends
13. Middle East and Africa Cervical Ripening Drugs Market Analysis, 2014 - 2018 and Forecast, 2019 - 2025
13.1.1. Drug Class Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.2. Drug Class Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.2.1. Prostaglandins
13.1.2.2. Oxytocin
13.1.2.3. Progesterone Receptor Antagonists
13.1.2.4. Relaxin
13.1.2.5. Estrogen
13.1.2.6. Others
13.1.3. Route of Administration Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Oral
13.1.3.2. Intravenous
13.1.3.3. Vaginal
13.1.4. Distribution Channel Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.4.1. Hospital Pharmacies
13.1.4.2. Retail Pharmacies
13.1.4.3. Others
13.1.5. Country Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.5.1. Gulf Cooperation Council (GCC) Countries
13.1.5.2. Israel
13.1.5.3. South Africa
13.1.5.4. Rest of MEA
13.1.6. MEA Cervical Ripening Drugs Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2019 – 2025
13.1.7. MEA Cervical Ripening Drugs Market Dynamics – Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Ferring B.V. (Switzerland)
14.2.2. Azanta A/S (Denmark)
14.2.3. Novartis AG (Switzerland)
14.2.4. GlaxoSmithKline plc (U.K.)
14.2.5. AstraZeneca plc (U.K.)
14.2.6. Pfizer, Inc. (U.S.)
14.2.7. Bayer AG (Germany)
15. Research Methodology
16. Key Assumptions and Acronyms
Research Methodology
It is a well-organized procedure to carry out research. We at Market Growth Insight follow global, all-inclusive & iterative research methodology to develop our research reports. We are using both the top down as well as bottom-up approaches for partitioning and evaluating the significant aspects of the market.
It is a systematic & strategic approach for conducting a market study. Our market research methodology is based on the concept that gives a detailed description of the factors behind an observation. Let us see the detailed market research methodology.
Primary Data Research
It is the very basic stage of research the raw data is obtained and collected on a boarded front.Data is constantly filtered to ensure that only validated and authenticated sources are considered. Moreover,information is also mined from a large group of reports in our vault, as well as various reputed paid databases. It is necessary to understand the entire value chain and in order to facilitate this; we gather information from raw material suppliers, distributors as well as buyers, for extensive knowledge of the market.
The technical issues and trends are acquired from reviews, technical discussion and trade journals. Moreover, the technical data is also accumulated from intellectual property prospective, focusing on a void area and freedom of movement. The industry elements regarding drivers, restraints, pricing trends are also collected. Subsequently, the material developed contains a wide range of original and unique information that is then further cross-validated and authenticated with published sources.
Statistical Model
Simulation models are responsible to estimate and forecast our market, and for each research, a unique model is created and customized. The data accumulated for market dynamics, innovation scene, application improvement, estimating trends is delivered into the model and analyzedsimultaneously. These components are examined on a comparative basis, and their impact on the figure of the frame is measured with the assistance of correlation, regression and time series investigation. Forecasting of the market is performed through the consolidation of economic tools, innovative examination, and industry experience along with domain expertise. Generally, economic models are utilized for short-termforecasting, technological market models are used for long-term forecasting of a market. These are based on an amalgamation of technology innovation, regulatory frameworks, economic outlook, and business principles. A bottom-up approach to the market estimation is preferred, with key regional markets analyzed as separate entities and integration of information to get a worldwide evaluation. This is very critical for a deep knowledge of the business as well as ensuring negligible mistakes. Below mentioned are some of the parameters are considered for forecasting
Market drivers and restraints, along with their current and expected impact
Raw material scenario and supply v/s price trends
Regulatory situation and expected developments
Current capacity and expected capacity additions up to 2025
Market driving organizations
The key targets of essential research are as per the following
To approve our information as far as exactness and adequacy
To pick up an understanding of the present market and future desires
We dole out weights to these parameters and evaluate their market effect utilizing weighted normal examination, to infer a normal market development rate.
This is the last advance in assessing and anticipating for our reports. Thorough essential meetings are led, on up close and personal and additionally via telephone to approve our discoveries and suppositions used to get them. Interviewees are drawn closer from driving organizations over the esteem chain including providers, innovation suppliers, area specialists,and purchasers in order to guarantee an all-encompassing and fair photo of the market. Essential meetings help in information approval, as well as give basic bits of knowledge into the market, current business situation and future desires and upgrade the nature of our reports. Every one of our assessments and figure is checked through comprehensive essential research with Key Industry Participants (KIPs) which ordinarily include:
Preliminary Investigation
This is the closing phase in estimating and forecasting for our reports. In this stage face to face and telephonic exhaustive interviews are conducted to validate our conclusion and assumptions used to obtain the final data. The leading companies across the value chain including suppliers, technology providers, domain experts,and purchasers are approaching the interviewees to ensure a holistic and unbiased view of the market. These interviews are led over the world, with language boundaries defeat with the guide of local staff and translators. Primary interviews in information validation as well as give critical insights into the market, current business outline and future expectations upgrade the quality of our reports. All our estimates and forecast are verified through exhaustive primary research with Key Industry Participants include
Leading market organizations
The key targets of primary research are as per the following:
To validate our data as far as exactness and adequacy
To pick up an understanding into the present market and future desires
Select License
Payment
Why Choose Us
